Gold(III) anti-cancer agents

Patent metadata

Field	Value
Publication number	US-9796734-B2
Application number	US-201715492698-A
Country	US
Kind code	B2
Filing date	Apr 20, 2017
Priority date	Dec 3, 2015
Publication date	Oct 24, 2017
Grant date	Oct 24, 2017

Abstract

A method for treating cancer and gold(III) complexes with diaminocyclohexane ligand as anticancer agents. Also described are a pharmaceutical composition incorporating the gold(III) complexes and a method of synthesizing the gold(III) complexes.

First claim

The invention claimed is:

1. A pharmaceutical composition, comprising:
at least one oil solvent selected from the group consisting of cocoa butter, a mono-glyceride, a di-glyceride, a tri-glyceride, a fatty acid and a polyethylene glycol, and
at least one of a gold(III) complex represented by formula (I) and a gold(III) complex represented by formula (II):

or a pharmaceutically acceptable salt, solvate, or prodrug thereof;
wherein each R 1 is independently selected from the group consisting of isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl;

each of R 2 is independently selected from the group consisting of a hydrogen, a halogen, a hydroxyl, an amino, a nitro, a cyano, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted arylalkyl, an optionally substituted heteroaryl, an optionally substituted alkoxyl, an optionally substituted aryl, an optionally substituted alkenyl, a N-monosubstituted amino group, and a N,N-disubstituted amino group;
X is selected from the group consisting of chloride, bromide, and iodide; and
the gold (III) complex comprises at least one pharmaceutically acceptable anion selected from the group consisting of salicylate, malate, maleate, succinate, tartrate, citrate and acetate.

2. The pharmaceutical composition of claim 1 , comprising the gold(III) complex of formula (I), wherein X is chloride.

3. The pharmaceutical composition of claim 1 , comprising the gold(III) complex of formula (II) wherein the at least one pharmaceutically acceptable anion is acetate.

4. The pharmaceutical composition of claim 1 , wherein each R 1 is independently selected from the group consisting of butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.

5. The pharmaceutical composition of claim 1 , wherein R 1 is isopropyl, R 2 is hydrogen, X is chloride, the oil solvent comprises a polyethylene glycol and the pharmaceutically acceptable anion is acetate.

6. The pharmaceutical composition of claim 1 , wherein R 1 is butyl, R 2 is hydrogen, X is chloride, the oil solvent comprises a polyethylene glycol and the pharmaceutically acceptable anion is acetate.

Assignees

• Univ King Fahd Pet & Minerals

Inventors

• Isab Anvarhusein A
• Altaf Muhammad

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57545

  of the ovaries · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C07F1/005 Primary

  without C-Metal linkages · CPC title

• C07F1/12

  Gold compounds · CPC title